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years did not uncover an underly-
ing cancer. Pyridostigmine par-
tially improved the patient for the 
first 2 years, and then DAP was
introduced with efficacy over the 
following 12 months. After another
phase of deterioration, two series 
of IvIg infusions were useful for 2
months. Then ephedrine sulfate
was prescribed at a dose of 200 mg/
d and the improvement was so 
impressive that we decided to
quantify the clinical and electro-
physiological (Edx) changes before
proceeding with ephedrine. 
The patient agreed to come for
five consecutive days. Muscle test-
ing and Hammersmith motor 
ability score (HMS) were per-
formed after the Edx tests. Edx 
studies were carried out by record-
ing CMAP from the abductor digiti 
minimi muscle (ADM). After a rest 
period, negative CMAP amplitude
was evoked at rest and immediately 
after 15 s SET [4]. The clinical and 
Edx changes were recorded each
day with 3 repetitions of the fol-
lowing 6 experimental conditions:
no treatment, 90 minutes after 
taking 60 mg pyridostigmine, 
25 mg 4-DAP, 100 mg ephedrine, 
pyridostigmine and DAP, ephe-
drine and DAP. The results are
shown in Fig.1. The highest HMS 
score correlates with the highest 
CMAP amplitude at rest obtained
during the association of DAP and 
ephedrine. After obtaining these 
positive results, ephedrine (200 mg/
d) and DAP (55 mg/d) were taken
continuously. Benefits were ob-
served after the patient was re-
viewed 1, 3 and 6 months after. A
moderate increase in blood pres-
sure was observed.
Ephedrine is a sympathomi-
metic drug with highly active
adrenergic effects on the heart and
vasculature [1], with untoward 
effects including hypertension and
tachyphylaxis [9]. The precise
mechanism of action in the muscle
is only partially known. An in vitro
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Sirs: A Cochrane review on 
treatment of Lambert-Eaton 
myasthenic syndrome (LEMS) 
underscores the efficacy of 3,4-
diaminopyridine (DAP) and of 
infusions of immunoglobulins 
(IvIg) [5]. The addition of pyrido-
stigmine may enhance effects of 
DAP. Ephedrine, a controversial
drug used in the past to treat
myasthenia gravis without proven 
benefit [8], has recently been used 
to improve patients with synaptic
congenital myasthenic syndrome 
[2]. Prompted by these observa-
tions, we evaluated the efficacy of 
ephedrine in one patient with 
idiopathic LEMS.
We describe a 60 year-old
female who developed progressive 
proximal limb muscle weakness
and generalized areflexia. A 300 %
potentiation of the compound
muscle action potential (CMAP) 
was demonstrated after a short
exercise test (SET) and antibodies 
against the voltage gated Ca2+
channel were positive. Diagnostic 
works-up over the following 5 
Edx study has shown that ephe-
drine increases quantal release of 
acetylcholine (Ach) [10], and may 
cause an open-channel blockade of 
the Ach receptors [6], which cannot
fully explain its beneficial effect. In 
a study using a rat model of myas-
thenia, the ephedrine effects were
considered unrelated to neuromus-
cular transmission but to suscepti-
bility to arousal [7]. In the reported 
Edx trial of ephedrine in synaptic
congenital myasthenic syndrome it
was concluded that ephedrine may 
exert a beneficial effect on muscle
function at a remote level as a
central effect [3]. In our patient we
observed a relative mismatch 
between the good clinical benefit 
(HMS) and surprisingly low CMAP
at rest during treatment with
ephedrine alone (see Fig.1, day 5), 
and this probably reflects the cen-
tral beneficial effect. Based on this, 
we can only speculate on a syner-
gic, but useful, effect of ephedrine
with DAP. As a limiting factor it 
should be emphasised that (i) we
do not know the safe and therapeu-
tic optimum dose of ephedrine per
kg body weight, and (ii) that pa-
tients should be monitored for
potential cardiovascular side
effects. Further trials are therefore 
needed to study the efficacy and 
tolerability of ephedrine in LEMS. 
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Fig. 1 A to C shows examples of raw data of two superimposed traces, the smallest corresponding to the CMAPs evoked at rest and the largest those evoked immediately 
after a 15 s of maximal voluntary exercise test. Data with no treatment or OFF (A); 90 min after taking ephedrine (B), and after taking ephedrine and DAP (C). Note the huge
potentiation obtained in B, as well as the synergic effect of the combined treatment with ephedrine and DAP on the CMAP obtained at rest in C. D Diagram showing the 
relationship between Hammersmith motor score (HMS), and CMAP amplitude. CMAPs obtained at rest (solid lines) and after exercise (dashed lines) were repeated 3 times. 
Amplitude is expressed as minimal and maximal, and median values, in the following experimental conditions during 5 different days (D): no treatment (OFF), 90 min after 
taking (i) 60 mg pyridostigmine (Mestinon), (ii) 25 mg 3,4-diaminopyridine (DAP), (iii) 100 mg ephedrine (EPH), (iv) DAP and pyridostigmine (DAP+ Mestinon) and (v)
ephedrine and DAP (EPH+DAP). The CMAPs obtained after exercise are quite similar in amplitude. The highest CMAP amplitude at rest was obtained at D6 (5.2 mV, DAP+ 
EPH), and correlates with the highest HMS score. The lowest CMAP amplitude obtained at rest was seen at D1 (Off), D2 (Mestinon) and D5 (EPH) (1.4 mV; 1.0 mV; 0.7 mV, 
respectively). Controversially, the HMS score under ephedrine is relatively high at day 5, probably reflecting the central effect of the drug 
